Table 2.
Response of Renca-MUC1 tumors to radiation and vaccine and tumor rechallenge
| aResponders/Cured | bImmune to Rechallenge | cIFN-γ Mean Spots ± SD | |||
|---|---|---|---|---|---|
| # Mice/Total | Percent | ||||
| Control | 0/36 | 0% | N/A | N/A |
|
| Vaccine | 0/7 | 0% | N/A | N/A | |
| Radiation | 2/43 | 4% | 0/6 | N/A | |
| Rad + Empty Vector | 3/20 | 15% | 3/3 | 140.4 ± 29.4 | |
| Rad + Vaccine (Schedule 1) | 11/45 | 24% | 9/9 | 156.4 ± 24.6 | |
| Vaccine + Rad (Schedule 2) | 17/29 | 58% | 7/8 | 152.6 ± 24.1 | |
Data were compiled from three independent experiments
aResponders/Cured: Responders were characterized by inhibition of tumor growth or complete tumor regression
bImmune to rechallenge: Responding and non-responding mice were challenged with 1x105 Renca-MUC1 cells injected in the left flank contralateral to the Renca-MUC1 primary tumor on day 40–60
cIFN-γ: Splenocytes were obtained from mice at 3-4 weeks after tumor rechallenge, stimulated with Renca-MUC1 cells in vitro and tested for production of IFN-γ in an ELISPOT assay